Manufacturer
Sanofi-Aventis Deutschland GmbH
Contents
Cabazitaxel
Indication
In combination w/ prednisone or prednisolone in adult patients w/ metastatic castration resistant prostate cancer previously treated w/ docetaxel-containing regimen.
Instruction
Administer via IV infusion.
Drug interaction
Increased plasma conc w/ strong CYP3A inhibitors eg, ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole. Decreased plasma conc w/ strong CYP3A inducers eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarb. Inhibited transport proteins of OATP1B1 substrates eg, statins, valsartan, repaglinide. Serious or fatal infections w/ live or live-attenuated vaccines.
Sanofi-Aventis Deutschland GmbH
Contents
Cabazitaxel
Indication
In combination w/ prednisone or prednisolone in adult patients w/ metastatic castration resistant prostate cancer previously treated w/ docetaxel-containing regimen.
Instruction
Administer via IV infusion.
Drug interaction
Increased plasma conc w/ strong CYP3A inhibitors eg, ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole. Decreased plasma conc w/ strong CYP3A inducers eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarb. Inhibited transport proteins of OATP1B1 substrates eg, statins, valsartan, repaglinide. Serious or fatal infections w/ live or live-attenuated vaccines.
Inquiry - Jevtana 60mg Concentrate and Solvent for Solution for Infusion